Because of that, Ahadova et al. urge us to consider at least three possible pathways, as follows: (a) progression from an adenoma with secondary inactivation of the MMR system, (b) progression from an initially MMR-deficient adenoma, and (c) progression from MMR-DCF directly to invasive cancer without adenoma formation [57]. Here, MRC1 is linked to adenoma.